Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

e-Consent in UK academic-led clinical trials: current practice, challenges and the need for more evidence.

Trials·2023

Same author

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Communication between plants: induced resistance in wild tobacco plants following clipping of neighboring sagebrush.

Oecologia·2017

Same author

Rapid infrared mapping for highly accurate automated histology in Barrett's oesophagus.

The Analyst·2016

Same author

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.

Statistical methods in medical research·2016

Same author

European consensus on the histopathology of inflammatory bowel disease.

Journal of Crohn's & colitis·2013

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer.

V C Petersen¹, K J Baxter, S B Love

¹Department of Histopathology and Cranfield Postgraduate Medical School in Gloucestershire, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.

|June 22, 2002

Summary

Identifying prognostic factors in Dukes

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Related Experiment Videos

Last Updated: Jun 23, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Area of Science:

Colorectal cancer research
Oncology
Pathology

Background:

Dukes' B colon carcinoma prognosis is difficult to determine.
Adjuvant chemotherapy efficacy for Dukes' B patients is unclear.
Need for objective pathological prognostic markers in colon cancer.

Purpose of the Study:

Assess pathological factors influencing prognosis in Dukes' B colon cancer.
Identify objective prognostic parameters for patient selection.
Inform treatment decisions for colon cancer patients.

Main Methods:

Prospective study of 268 Dukes' B colon cancer resections.
Meticulous pathological assessment of prognostic factors.
Comprehensive patient follow-up system utilized.

Main Results:

Four independent prognostic factors identified: peritoneal involvement, venous spread, surgical margin involvement, and perforation.
Multivariate analysis confirmed significance of these factors.
A cumulative scoring system combining these factors created prognostic groups.

Conclusions:

Cumulative prognostic index stratifies Dukes' B colon cancer patients.
Objective patient selection for adjuvant therapy is enabled.
Facilitates patient stratification in clinical trials for colon cancer.